ClinicalTrials.gg
CompletedNCT04281342Updated Nov 23, 2022

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

A Phase 1 interventional study of Aprocitentan 25 mg and Aprocitentan 100 mg in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic doses of aprocitentan do not have a clinically relevant effect on the QT interval.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.
  • No findings on the physical examination at screening.
  • 18.0 to 30.0 kg/m2 (inclusive) at screening.
  • Systolic blood pressure 90-140 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 50-90 bpm (all inclusive), measured on the same arm, after 5 minutes in the supine position at screening.
  • 12-lead safety : less than 450 ms for male subjects and less than 470 ms for female subjects, QRS less than 110 ms, PR less than 220 ms, and resting HR greater than 50 bpm and less than 90 bpm with no clinically relevant abnormalities on 12-lead ECG after at least 5 min in the supine position at Screening and on Day 1 pre-dose of Period 1.
  • No clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry) at screening.
  • Negative results from urine drug screen, urine cotinine test, and breath alcohol tests at screening and on Day -1 of each period.
  • A woman of (WoCBP) is eligible only if the following applies:

    • Negative serum pregnancy test at screening.
    • Negative urine pregnancy test on Day -1 of each period.
    • Agreement to consistently and correctly use a highly effective method of from screening up to at least 30 days after last study treatment administration in the last period with in-between periods included.
  • Women of non-childbearing potential (WoNCBP) must meet at least one of the following criteria:

    • Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy,
    • Confirmed premature ovarian failure,
    • .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Previous exposure to aprocitentan or macitentan.
  • Known to aprocitentan or macitentan or any of the drug product , or treatments of the same class.
  • Any or known hypersensitivity to moxifloxacin or any of the drug product excipients or to other fluoroquinolone antibiotics.
  • Known hypersensitivity or allergy to natural rubber latex.
  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the study.
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 2 weeks or 5 t½ (whichever is longer) prior to first study treatment administration with the exception of in female subjects.
  • History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, second- or third-degree atrioventricular block, long syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation) or hypokalemia.
  • Legal incapacity or limited legal capacity at screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Aprocitentan 25 mg

    Therapeutic dose level

    Drug: Aprocitentan 25 mg

  • Experimental
    Aprocitentan 100 mg

    Supratherapeutic dose level

    Drug: Aprocitentan 100 mg

  • Placebo comparator
    Matching placebo

    Drug: Matching placebo

  • Other
    Moxifloxacin

    Other: Moxifloxacin control to establish assay sensitivity

Interventions

  • Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.

    Also known as: ACT-132577

  • Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.

    Also known as: ACT-132577

  • DrugMatching placebo

    Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.

  • OtherMoxifloxacin control to establish assay sensitivity

    Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.

06

What researchers measure

Primary outcomes

  1. Placebo-corrected change from baseline in QT interval corrected with Fridericia's formula (ΔΔQTcF)

    Time frame: Multiple predefined time points related to study treatment administration on Day 1 and Day 10 to 11 of each treatment.

Secondary outcomes

  1. Aprocitentan trough plasma concentrations (Ctrough)

    Time frame: Day 2 to Day 9

  2. Aprocitentan plasma Cmax, first dose

    Time frame: Pre-defined times on the first dosing day (Day 1) up to 15 hours after last dose

  3. Aprocitentan plasma Cmax, steady state

    Time frame: Pre-defined times on the last dosing day (Day 10) up to 15 hours after last dose

  4. Area under the plasma concentration-time curve (AUCτ) during a dosage interval (τ) of aprocitentan

    Time frame: Day 1 to Day 10

  5. Aprocitentan attainment of steady-state conditions

    Time frame: Day 1 to Day 10

  6. Accumulation index between the first and the last dosing day of aprocitentan

    Time frame: Day 1; Day 10

07

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, Baden-Württemberg 68167, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Aug 2021, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Feb 24, 2020
StartActual
Jan 14, 2020
Primary completionActual
Aug 3, 2021
CompletionActual
Sep 3, 2021
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04281342
Responsible party
Sponsor
First posted
Feb 24, 2020
Start date
Jan 14, 2020
Primary completion
Aug 3, 2021
Completion
Sep 3, 2021
Last update
Nov 23, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion